Mark Klempner to Treatment Outcome
This is a "connection" page, showing publications Mark Klempner has written about Treatment Outcome.
Connection Strength
0.190
-
Wang Y, Kern A, Boatright NK, Schiller ZA, Sadowski A, Ejemel M, Souders CA, Reimann KA, Hu L, Thomas WD, Klempner MS. Pre-exposure Prophylaxis With OspA-Specific Human Monoclonal Antibodies Protects Mice Against Tick Transmission of Lyme Disease Spirochetes. J Infect Dis. 2016 07 15; 214(2):205-11.
Score: 0.063
-
Klempner MS, Baker PJ, Shapiro ED, Marques A, Dattwyler RJ, Halperin JJ, Wormser GP. Treatment trials for post-Lyme disease symptoms revisited. Am J Med. 2013 Aug; 126(8):665-9.
Score: 0.051
-
Klempner MS. Controlled trials of antibiotic treatment in patients with post-treatment chronic Lyme disease. Vector Borne Zoonotic Dis. 2002; 2(4):255-63.
Score: 0.023
-
Hu LT, Klempner MS. Update on the prevention, diagnosis, and treatment of Lyme disease. Adv Intern Med. 2001; 46:247-75.
Score: 0.022
-
Klempner MS. Beyond us versus them. J Gen Intern Med. 1999 Aug; 14(8):514-5.
Score: 0.020
-
Fleming RV, Marques AR, Klempner MS, Schmid CH, Dally LG, Martin DS, Philipp MT. Pre-treatment and post-treatment assessment of the C(6) test in patients with persistent symptoms and a history of Lyme borreliosis. Eur J Clin Microbiol Infect Dis. 2004 Aug; 23(8):615-8.
Score: 0.007
-
Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, Haselby R, Hilton E, Kunkel M, Adler-Klein D, Doherty T, Evans J, Molloy PJ, Seidner AL, Sabetta JR, Simon HJ, Klempner MS, Mays J, Marks D, Malawista SE. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med. 1998 Jul 23; 339(4):216-22.
Score: 0.005